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Abstract
Background: Unfractionated heparin is the most common anticoagulant used in haemodialysis (HD), although it
has many potential adverse effects. Citrate dialysate (CD) has an anticoagulant effect which may allow reduction in
cumulative heparin dose (CHD) compared to standard acetate dialysate (AD).
Methods: This double-blinded, randomised, cross-over trial of chronic haemodialysis patients determines if CD
allows reduction in CHD during HD compared with AD. After enrolment, intradialytic heparin is minimised during a
two-week run-in period using a standardised protocol based on a visual clotting score. Patients still requiring
intradialytic heparin after the run-in period are randomised to two weeks of HD with AD followed by two weeks of
CD (Sequence 1) or two weeks of HD with CD followed by two weeks of AD (Sequence 2). The primary outcome is
the change in CHD with CD compared with AD. Secondary outcomes include metabolic and haemodynamic
parameters, and dialysis adequacy.
Discussion: This randomised controlled trial will determine the impact of CD compared with AD on CHD during HD.
Trial registration: ClinicalTrials.gov NCT01466959
Keywords: Citrate dialysate, Hemodialysis, Haemodialysis, Unfractionated heparin, Anticoagulation, Randomised
controlled trial
Background
During haemodialysis (HD), blood is exposed to an
extracorporeal circuit which activates thrombogenic
pathways and clotting [1]. Clotting in the dialysis circuit
decreases HD efficiency, and increases nursing workload
and costs [2]. Even subclinical clotting of the dialysis cir-
cuit may reduce effective dialyser surface area and pore
size, decreasing both small and middle solute clearance.
Additionally, activation of the coagulation pathway in
HD patients may be associated with increased inflamma-
tion and accelerated atherosclerosis [3].
In North America, unfractionated heparin is the most
common anticoagulant used to prevent clotting during
HD [4, 5]. Although effective and inexpensive, it has a nar-
row therapeutic window without adverse bleeding. Since
heparin provides systemic anticoagulation, it is contraindi-
cated in the setting of active bleeding, trauma, pericarditis,
intracerebral haemorrhage, thrombocytopenia, coagulopa-
thy, and peri-operative care [6–9]. Furthermore, heparin
may lead to osteoporosis, dyslipidaemia, hyperkalaemia,
and immune-mediated heparin-induced thrombocytopenia
[2, 10–16].
An alternative to systemic heparin anticoagulation for
HD is citrate dialysate (CD). CD contains a small
amount of citric acid rather than acetic acid as the acid-
ifying agent, at one-fifth the concentration of citric acid
used for regional citrate anticoagulation. There are sev-
eral observational studies [17–27] and two randomised
trials using CD in HD patients [28, 29]. These studies
demonstrate that CD is associated with decreased clot-
ting of the haemodialysis circuit [17], decreased need for
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anticoagulation [24, 26, 29], increased dialyser reuse [19],
and increased small and middle solute clearance [18–20,
26–28, 30]. These benefits are from an anticoagulation ef-
fect that is limited to the extracorporeal circuit without
systemic coagulation activation [28]. Other associated
benefits of CD include decreased acidosis [18, 22, 28], de-
creased inflammation [27], decreased oxidative stress [25],
improved anaemia [22], improved nutrition [22], and
greater haemodynamic stability [21, 28, 31]. CD is well tol-
erated with no unstable metabolic parameters and no doc-
umented adverse effects [18, 22, 29], even in paediatric
patients with acute kidney injury [32], in critically ill pa-
tients [17], and patients with advanced liver failure [33].
We describe our protocol for a six-week, double-
blinded, randomised cross-over trial that investigates
whether CD results in reduced cumulative heparin dose
(CHD) compared to acetate dialysate (AD) in chronic
HD patients. Secondary outcomes address safety con-
cerns, and include metabolic and haemodynamic param-
eters, and dialysis adequacy.
Methods
Study setting
This randomised crossover clinical trial is performed
within three community HD units in Calgary, Alberta,
Canada, where unfractionated heparin is used for stand-
ard intradialytic anticoagulation. All participants provide
written informed consent. The study protocol is ap-
proved by the Conjoint Health Research Ethics Board at
the University of Calgary, and is conducted in accord-
ance with the Declaration of Helsinki (ClinicalTrials.gov,
NCT01466959).
Study population
Eligible patients are ≥ 18 years, and on outpatient con-
ventional HD three times per week for at least three
months. Exclusion criteria include: contraindication to
heparin, heparin-free HD, known clotting disorder, war-
farin therapy, dialysing with a dysfunctional central ven-
ous catheter (blood flow rate consistently < 300 mL/min
and/or frequent use of thrombolytic), vascular access
dysfunction, planned vascular access conversion or pro-
cedure during the study period, use of high calcium di-
alysate, active medical issue, planned kidney transplant
during the study period, planned conversion of dialysis
modality (peritoneal dialysis, nocturnal dialysis) during
the study period, or inability to provide informed
consent. Patients with recent modifications to their
erythropoiesis-stimulating agent dose are reviewed by
the investigator for eligibility.
Study protocol
After enrolment, each patient’s dose of intradialytic hep-
arin is minimised during a two-week run-in period
(Fig. 1) using study protocol (Table 1) which is based on
a standardised visual clotting score [34]. The visual clot-
ting score is quantified by inspecting the venous cham-
ber and all four quadrants of the dialyser at the end of
the HD session (0: clear dialyser/no clots; 1: few strands/
small clots; 2: half clotted; 3: three-quarters clotted; 4:
completely clotted, unable to return blood) (Table 1).
The heparin dose is reduced to reach a target visual clot-
ting score of 2, then increased slightly and maintained,
to achieve the lowest possible dose required to prevent
clotting (Table 1). The CHD during the last HD session
of the run-in period is considered to be the patient’s
baseline heparin dose. Patients still requiring intradialy-
tic heparin after the two-week run-in period, and who
still meet inclusion and exclusion criteria, are rando-
mised to one of two treatment sequences (Fig. 1). For se-
quence 1, patients undergo six HD sessions over two
weeks with AD (control), followed by six HD sessions
over two weeks with CD (intervention). For sequence 2,
patients undergo six HD sessions over two weeks with
CD (intervention), followed by two weeks of AD (con-
trol) (Fig. 1). Patients begin each study phase (AD and
CD) with their baseline intradialytic heparin dose, deter-
mined at the end of the run-in period. Nurses subse-
quently adjust intradialytic heparin dose per protocol
(Table 1) during each HD session of each study phase.
At the end of the first study phase (two weeks), a 68-h
washout period ensures no potential for a carry-over ef-
fect. After the wash-out period, patients cross-over to
the other treatment for the next two weeks beginning
again with their baseline heparin dose (Fig. 1). A two-
week duration for each strategy is chosen to ensure ad-
equate time to attain the minimum required heparin dose.
Randomisation is determined by a computer generated
random number list and concealed in sequentially num-
bered, opaque, sealed envelopes to ensure allocation con-
cealment. Following informed consent and enrolment, the
envelope containing allocation sequence is provided to the
research coordinator who implements the sequence as-
signment according to protocol. The intervention and
control dialysates, CD and AD, are packaged identically by
the manufacturer (Chief Medical Supplies, Ltd., Calgary,
Alberta, Canada) for blinding of investigators, patients,
and health care staff. All data is confidential, and entered
into electronic records by an independent data entry clerk
who is blinded to patient allocation.
All study patients are dialysed using Gambro Phoenix®
dialysis systems (Gambro-Hospal, Mirandola, Italy) at
least three times per week. Each patient’s target weight
and dialysis prescription are optimised at the study start
by the rounding nephrologist using clinical assessment.
Standard dialysis prescriptions (blood flow rate 300–
450 mL/min, dialysate flow rate 500 mL/min, dialysate
temperature 0.5 °C less than patient temperature,
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dialysate sodium 137 mmol/L) are maintained unless
otherwise prescribed. Dialysers are high-flux, polysulfone
(REXEED™, Asahi Kasei Medical Co. Ltd., Tokyo, Japan).
HD prescriptions, target weights, and antihypertensive
medications are not changed during the study period.
The intervention dialysate, CD, contains 2.4 mEq/L of
Run-in period for 2 weeks 
(6 HD sessions)
Heparin dose minimised to baseline
Randomisation
AD for 2 weeks
(6 HD sessions)
begin with baseline heparin dose, 
reduce heparin per protocol
Washout for 68 hours
CD for 2 weeks
(6 HD sessions)
begin with baseline heparin dose, 
reduce heparin per protocol
CD for 2 weeks
(6 HD sessions)
begin with baseline heparin dose, 
reduce heparin per protocol
Washout for 68 hours
AD for 2 weeks
(6 HD session)
begin with baseline heparin dose, 
reduce heparin per protocol
Exclude if heparin dose is 0
Sequence 1 Sequence 2
Fig. 1 Study Flow Diagram
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citric acid (Citrasate®, Advanced Renal Technologies,
Bellevue, WA), and the control dialysate, AD, contains
4 mmol/L of acetic acid.
Study endpoints
Primary outcome measures are the absolute and percent
change in CHD from baseline with CD compared with
AD. CHD is defined as the total heparin received per dialy-
sis session. Secondary outcomes are the effect of CD com-
pared with AD on systemic anticoagulation (prothrombin
time [PT]/international normalised ratio [INR], activated
partial thromboplastin time [aPTT]), intradialytic meta-
bolic parameters (serum total serum calcium, ionized cal-
cium, magnesium, bicarbonate), anaemia, haemodynamic
stability (blood pressure, heart rate, corrected QT interval,
number of HD sessions complicated by intradialytic
hypotension), dialysis adequacy (single pool Kt/V, urea re-
duction ratio, beta-2-microglobulin [B2M]), systematic in-
flammation (C-reactive protein [CRP]), bleeding time after
HD, and bleeding events. Also, the visual clotting score
and the dialyser fibre bundle volume (FBV) (as measured
by the ultrasound dilution technique [35]) are correlated.
Lastly, the intra-rater and inter-rater reliability of the visual
clotting score is assessed.
Data collection
Baseline characteristics
Baseline patient demographics (age, gender, HD vintage,
race), comorbidities, cause of ESRD, labs, and HD pre-
scription (dialyser, dialysate composition and temperature,
blood and dialysate flow rates, target weight, anticoagula-
tion) are extracted from HD charts and the Southern
Alberta Renal Program database [36].
Cumulative heparin dose
The CHD is calculated per HD session, and determined
from HD run sheets. Specifically, CHD is the initial
heparin bolus, plus the hourly heparin infusion rate
multiplied by the time on HD during which heparin is
infused, per session, in heparin units. For the primary
outcome, the CHD for the last two HD runs of each
study phase are recorded, averaged, and used to calcu-
late change from baseline CHD. The last two HD ses-
sions of each phase is chosen to allow adequate time in
each phase for heparin dose minimisation.
Visual clotting score, inter-and intra-rater reliability
The clotting score is a visual grade of dialyser and ven-
ous chamber clotting (Table 1). To ensure consistency,
scoring of dialyser/venous chamber clotting for heparin
dose adjustments are performed at the end of each HD
session by a single, trained research nurse. A second HD
nurse independently and blindly scores the dialyser/ven-
ous chamber appearance; this second clotting score is
recorded to assess inter-rater reliability, but is not used
to adjust the heparin dose per protocol. To assess for
intra-rater reliability, at the end of each HD session dur-
ing the run-in phase, the dialyser quadrants are captured
in four photographs by the same trained research nurse,
using a digital camera on a tripod, with standardised
lighting, at a standardised distance and height from the
dialyser. The dialyser is rotated by 90° for each of the
four photographs, to visually capture the full circumfer-
ential view of the dialyser. The photographs are re-
presented in a blinded fashion to the same research
nurse at a later date to be re-scored.
Metabolic, anticoagulation, and inflammatory parameters
Serum total calcium, ionized calcium, albumin, magne-
sium, bicarbonate, haemoglobin, urea, PT/INR, aPTT,
B2M, and CRP are collected at the beginning of the first
HD session of the study (whether randomised to Se-
quence 1 or 2), and drawn again both pre and post HD
for the last HD sessions of each study phase. Ionized
Table 1 Visual Clotting Score and Heparin Protocol
Clotting Score Dialyser/Venous Chamber Appearance
(at the end of each HD session)
Heparin Dose Adjustment (for the next HD session)
0 Clear Decreasea boost by 200 units and decrease running dose by 200 units/h
1 Few strands/small clot Decreasea boost by 200 units and decrease running dose by 200 units/h
2 ½ clotted Increase boost by 200 units and increase running dose by 200 units/h and
maintain this new heparin dose for the remainder of this study phase only.
3 ¾ clotted (able to return blood) Increase boost by 300 units and increase running dose by 300 units/h
4 Completely clotted (unable to return blood) Increase boost by 400 units and increase running dose by 400 units/h
HD haemodialysis
NOTE
1) If there is unusually prolonged bleeding from vascular access sites post-HD, for the next HD session, decreasea heparin running dose by 200 units/h and turn
heparin off 30 min earlier than usual
2) If there is a discrepancy in score between the dialyser and the venous chamber, the heparin dose adjustment is based on the dialyser clotting score
aThe minimum possible heparin boost and running dose are 500 units (boost) and 500 units/h. If the heparin dose is to be decreased to less than 500 units (boost
and/or running dose) for the next HD session, discontinue the boost and/or the running dose
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calcium is drawn pre and post HD during the first and
last HD session in each study phase.
Haemodynamic parameters
Blood pressure and heart rate are measured and re-
corded by HD nurses pre and post HD, and every
30 min during HD. The number of HD sessions compli-
cated by intradialytic hypotension (IDH) during each
study phase is recorded. IDH is defined as a drop in the
systolic blood pressure (SBP) by ≥ 20 mmHg to <
100 mmHg with patient symptoms or nursing/physician
intervention. If the patient’s pre-HD SBP is < 100 mmHg,
then IDH is defined as a drop in SBP ≥ 10 mmHg with
patient symptoms or nursing/physician intervention. An
electrocardiogram is performed at baseline (after the
run-in phase), as well as pre and post HD during the last
HD session in each two week study phase.
Dialysis adequacy
Single pool Kt/V is determined for each HD session using
Diascan® (Hospal-Gambro, Mirandola, Italy), which mea-
sures the dialysance of sodium through the dialyser mem-
brane corrected for recirculation and ultrafiltration [37],
and which is a validated method for measuring urea clear-
ance [38]. In addition, the urea reduction ratio is calcu-
lated for the last HD session of each study phase using the
equation ((urea pre—urea post)/urea pre).
Bleeding time and bleeding events
For the last two HD sessions of each study phase, the
bleeding time post-HD is recorded and averaged in patients
who have a fistula or graft as their vascular access. Bleeding
events are documented and classified into: 1) major bleed-
ing (fatal bleeding, overt bleeding associated with a haemo-
globin drop ≥ 20 g/L and/or transfusion with 2 units of red
blood cells, retroperitoneal/intracranial/intraspinal/intra-
ocular/pericardial/non-traumatic intra-articular bleeding),
2) clinically important non-major bleeding (clinically overt
bleeding requiring hospital admission or visit to a medical
facility or leading to intervention), and 3) minor bleeding
(any bleeding episode not meeting criteria for the preceding
bleeding categories).
Fibre bundle volume
FBV is the space within the blood compartment of hol-
low fibre dialysers [35]. Using the ultrasound dilution
technique (Transonic® HD02 monitor, Transonic Sys-
tems Inc.®, Ithaca, NY, USA), dialyser FBV is measured
twice (and the mean recorded) during both the first and
last 30 min of the mid-week HD sessions throughout the
entire study period (including the run-in phase). The
change in FBV during HD represents the quantity of clot
in the dialyser [35] and is determined using the equation
((FBV pre—FBV post)/FBV pre).
Sample size calculations
Previous studies have demonstrated that CHD is reduced
by 30 % with the use of CD [39]. Locally in Calgary, the
mean CHD is 3000 units (standard deviation 900 units)
per HD session in 85 % of HD patients. Based on this, and
taking into account a 30 % dropout rate, we estimate that
20 patients are required to demonstrate a 30 % (1000
units) reduction in CHD with CD compared to AD (alpha
0.05, power 80 %). We use the method of Frison and
Pocock for the ANCOVA model, and Rabe-Hesketh and
Skrondal for the mixed linear model solution (StataCorp
LP version SE 11.0, College Station, TX, USA).
Statistical analysis
Baseline characteristics will be presented as means and
95 % confidence intervals (CIs) or medians and inter-
quartile range (IQR) for continuous variables, and abso-
lute and relative proportions for categorical variables. To
determine the effect of CD compared with AD on reduc-
tion in CHD (the primary outcome) a random intercept
linear mixed model will be used, with CD or AD as the
main exposure, subjects as source of random effects,
baseline heparin dose values as covariate (at least 2 of 3
measures from the first of two weeks of each period),
and final heparin dose values as outcome (at least 2 of 3
measures of the second week of each period). This
model takes into account the correlation of data caused
by repeated measures for each subject given the cross-
over design of the study. Treatment, treatment period,
and treatment sequence will be modelled as fixed effects.
If there is no evidence of period or carry-over effects, all
comparisons will be presented relative to AD, without
the need for consideration of carry-over effects.
Discussion
CD has the potential to decrease intradialytic anticoagu-
lation requirements, and improve patient outcomes.
However, existing literature comparing CD to AD is
limited. Most studies are small, observational in nature,
and focus on dialysis adequacy, dialyser reuse/clotting,
or metabolic/inflammatory/haemodynamic parameters
[17–23, 25, 27]. Only two prospective randomised stud-
ies comparing CD to AD have been performed. One
single-centre, unblinded crossover study randomised
twenty-three maintenance HD patients to first receive
CD without anticoagulation or AD with a Tinzaparin
bolus [29]. If the CD session revealed early clotting of
the venous chamber or dialyser, a Tinzaparin bolus at
half the usual dose could be given, and repeated once.
During the HD sessions with CD, 50 % of patients did
not require anticoagulation, 32 % required a reduced
Tinzaparin bolus, and 18 % stopped HD early due to
clotting without Tinzaparin. Of those who received antic-
oagulation with CD, the median dose of Tinzaparin
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received was 40 % of the standard dose. There was no dif-
ference in dialysis adequacy between groups [29]. The
main limitation of this study is that the two groups were
not treated equally; unlike the CD group, no attempt was
made to reduce anticoagulation in the AD group [29]. An-
other single-centre, single-blinded, crossover study rando-
mised twenty-five clinically stable maintenance HD
patients to receive either AD or CD weekly in an alternat-
ing fashion for four weeks [28]. The primary outcome was
systemic haemodynamics; secondary outcomes were co-
agulation activation, acid–base balance, calcium balance,
and dialysis adequacy. Compared with AD, the CD group
had significantly lower blood pressure and peripheral vas-
cular resistance without any difference in stroke volume.
However, the decrease in SBP was ablated with dialysate
calcium supplementation in the last study week. CD re-
sulted in a significant increase in pre-HD bicarbonate
levels, lower post-HD ionized calcium, and higher Kt/V
without any effect on coagulation parameters [28]. This
study did not assess the effect of CD on intradialytic
heparin dose (heparin was used per usual protocol in
both groups); the effect of CD on IDH was also not ex-
amined [28].
Four observational studies specifically address heparin
use with CD in maintenance HD patients [24, 26, 30, 39].
One study included 277 chronic HD patients from eight
HD units in an eight-week long, open-label, sequential
four-phase study [26]. The primary outcome was change
in mean effective conductivity clearance with CD (and re-
duced heparin) versus AD (and standard heparin dose).
Each study phase was two weeks long (6 HD sessions). In
the first baseline phase, patients received AD and 100 % of
their standard heparin dose. In subsequent phases, pa-
tients received CD and decreasing amounts of heparin
(second phase: CD and 100 % of standard heparin dose;
third phase: CD and 80 % of standard heparin dose; fourth
phase: CD and 2/3 of standard heparin dose). At the end
of the study, there was no difference in dialysis adequacy
between baseline (AD with 100 % heparin) and subse-
quent phases (CD with decreased heparin). Even with a
33 % reduction in heparin, there was no difference in HD
circuit clotting, and dialysis adequacy was maintained
[26]. This study did not assess if a reduced heparin dose
was possible with AD [26]. In another prospective study,
chlorhydric-acid based dialysate was compared with CD
in ten patients treated with post-dilution online haemodia-
filtration [24]. During treatments with CD, the heparin
dose was decreased by half, then completely discontinued.
In 120 CD sessions without heparin, dialysis adequacy was
unchanged, and only one clotting episode related to vas-
cular access stenosis was experienced [24]. Two further
observational studies, published in abstract form only,
included 20 and 31 chronic HD patients, respectively,
who had prolonged bleeding from vascular access
needling sites post HD. Patients were switched from
AD to CD, and intradialytic heparin doses were reduced
by 30 % [19, 39] after two months, and 55 % [30] after
four months, respectively. In both studies, heparin re-
duction with CD was achieved without decrease in dia-
lysis adequacy [30, 39].
Although existing literature suggests that CD use dur-
ing chronic HD allows intradialytic heparin reduction
without sacrifice of dialysis dose, and without other ad-
verse effects, this has yet to be investigated in a rigorous
trial. We have presented in detail the motivation, design
and strategy for our randomised controlled trial, includ-
ing methods of recruitment, randomisation, allocation
concealment, dialysis intervention, outcome assessment,
and data collection. The study protocol is developed ac-
cording to Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) 2013 [40]; results will
be reported following the Consolidated Standards of
Reporting Trials (CONSORT) statement [41].
In summary, our randomised crossover trial of chronic
HD patients will determine if CD decreases intradialytic
heparin requirements, and its affect on haemodynamic
stability and dialysis adequacy. Our study will answer a
clinically relevant and important question which has not
previously been addressed by a well-designed rando-
mised trial.
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